Thursday, 26 July 2018 02:12

Great News For Australian Patients - MAVIRET® (glecaprevir/pibrentasvir) PBS listed on 1 August 2018

Written by
Rate this item
(0 votes)

News Flash

MAVIRET® (glecaprevir/pibrentasvir) was listed on the PBS in Australia today.

  • AbbVie is pleased to announce that MAVIRET is to be listed on the PBS on 1 August 2018 for the treatment of chronic hepatitis C virus (HCV) infection in adults.
  • MAVIRET is a new 8 week pangenotypic treatment for treatment-naïve non-cirrhotic HCV adult patients.
  • In clinical trials, MAVIRET demonstrated 98% cure* rate in the ITT population (n/N=943/965) and 99% in the mITT population‡ (n/N=943/952) in treatment-naïve, non-cirrhotic patients pooled across GT1-6 with 8 weeks of treatment3, and a 0.1% discontinuation rate due to adverse events

*Cure defined as HCV RNA below the lower limit of detection at 12 weeks post end-of-treatment (SVR12)

An estimated 9 out of 10 of the remaining people living with chronic HCV are treatment-naïve and non-cirrhotic and may be eligible for 8 weeks of therapy with MAVIRET

Read 549 times Last modified on Wednesday, 01 August 2018 01:21

Copyright © 2015-2017 FixHepC

Back to Top